Catalog No.
Product Name
Application
Product Information
Citations
-
COX-2 Inhibitor
COX-2-IN-60 is a potent and selective inhibitor of cyclooxygenase-2 (COX-2), demonstrating an IC50 of 0.06 μM and approximately 100-fold selectivity over COX-1. This compound significantly reduces oxidative stress and neuroinflammatory cytokines, effectively counteracting epileptogenesis. In preclinical studies utilizing a pilocarpine-induced seizure mouse model, COX-2-IN-60 exhibited substantial anticonvulsant effects while protecting against hippocampal injury. Its application in research relates to neuroinflammatory pathways and epilepsy mechanisms. -
ROS/iNOS/TNF-α/COX-2 Inhibitor
Callistephin chloride is an anthocyanin that functions as an inhibitor of reactive oxygen species (ROS) and nitric oxide synthase (iNOS), as well as tumor necrosis factor-alpha (TNF-α) and cyclooxygenase-2 (COX-2). This compound regulates the expression of inflammatory and apoptosis-related proteins by inhibiting p38 phosphorylation, thereby enhancing the protective effects against microglial cell damage. Callistephin chloride also significantly reduces ROS levels, mitigates glutamate excitotoxicity, and provides neuroprotection to cerebellar granule neurons. Additionally, it inhibits the proliferation and metastasis of breast cancer cells through the induction of apoptosis. -
COX-2/HDAC Inhibitor
Andrographidine E is an inhibitor of cyclooxygenase-2 (COX-2) and histone deacetylases (HDAC), with an IC50 of 19 μM for COX-2 and a strong affinity for HDAC1 and HDAC3. This compound selectively binds to macrophages, suggesting its potential as an immunotargeting agent. Andrographidine E is valuable for research applications focused on inflammation and immune modulation. -
COX-1/cAMP Phosphodiesterase Inhibitor
Triflusal is a dual inhibitor of Cyclooxygenase-1 (COX-1) and cAMP phosphodiesterase, which penetrates the blood-brain barrier. It effectively inhibits platelet aggregation, nuclear factor kappa B (NF-κB) activation, inducible nitric oxide synthase (iNOS) activity, and prostaglandin synthesis in ischemic tissues. Additionally, Triflusal enhances neutrophil nitric oxide production, endothelial nitric oxide synthase (eNOS) expression, and constitutive nitric oxide synthase (cNOS) activity. This compound is valuable for investigating thromboembolic and ischemic diseases of the cardiovascular and cerebrovascular systems, as well as Alzheimer's disease pathology. -
COX Inhibitor
Pentagamavunon-1 (PGV-1) is a COX-2 inhibitor that modulates multiple molecular pathways to induce apoptosis. This Curcumin analog exhibits notable oral bioactivity and suppresses key angiogenic factors, including vascular endothelial growth factor (VEGF). Additionally, PGV-1 inhibits NF-κB activation, highlighting its potential in cancer research and therapeutic applications targeting inflammation and tumor progression. -
EGFR/HER2/CDK9/COX-2 Inhibitor
CDK9-IN-41 is a potent inhibitor of CDK9, EGFR, HER2, and COX-2, exhibiting IC50 values of 192.81 nM, 254.03 nM, 238.81 nM, and 775 nM respectively. This compound demonstrates significant antitumor activity across various cancer cell lines, including leukemia, colon, melanoma, ovarian, and breast cancer. It serves as a valuable tool for exploring the role of these kinases in cancer biology and therapeutic applications. -
COX Inhibitor
[8]-Shogaol is a potent inhibitor of cyclooxygenase (COX), specifically targeting COX-2 with an IC50 of 17.5 μM. This compound exhibits significant antiplatelet properties (IC50=5 μM) and demonstrates anti-cancer and anti-inflammatory activities. Additionally, [8]-Shogaol modulates key signaling pathways by inhibiting TAK1, IKK, and Akt, thereby influencing MAPK signaling and alleviating synovitis. Its unique pharmacological profile makes it a valuable reagent for research in cancer, inflammation, and cardiovascular diseases. -
COX Inhibitor
Diclofenac potassium is a potent nonselective inhibitor of cyclooxygenase (COX) enzymes, demonstrating IC50 values of 4 nM for human COX-1 and 1.3 nM for human COX-2 in CHO cells, along with 5.1 μM and 0.84 μM for ovine COX-1 and COX-2, respectively. This reagent exhibits significant anti-inflammatory properties and is particularly effective in inducing apoptosis in neural stem cells through the activation of the caspase cascade. It is widely used in research studies focusing on inflammatory pathways and neural stem cell biology. -
iNOS/COX-2 Inhibitor
Ermanin is a flavonoid extracted from Tanacetum microphyllum, known for its potent inhibitory effects on inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2). Its biological activities include anti-inflammatory, anti-tuberculous, and anti-viral/bacterial properties, making it a valuable reagent in research related to inflammation and infectious diseases. Ermanin is useful for exploring the pathways associated with nitric oxide production and prostaglandin synthesis in various biological contexts. -
COX Inhibitor
α-Spinasterol is a selective inhibitor of cyclooxygenase enzymes COX-1 and COX-2, exhibiting IC50 values of 16.17 μM and 7.76 μM, respectively. This compound demonstrates a range of biological activities, including antibacterial, anti-inflammatory, antidepressant, and antioxidant effects. Furthermore, it can effectively cross the blood-brain barrier and has shown potential in improving diabetes in murine models, making it a valuable tool for research in inflammatory disorders and neurological conditions. -
COX-1/2 Inhibitor
2-(p-Tolyl)propanoic acid is a selective inhibitor of COX-1 and COX-2 enzymes, displaying IC50 values of 38.23 μM and 64.30 μM, respectively. This compound exhibits antimicrobial properties and is relevant for research on bacterial pathogens such as Escherichia coli, Enterococcus faecalis, Listeria monocytogenes, and Staphylococcus aureus. Its mechanism of action positions it as a valuable tool for investigating inflammatory processes and antimicrobial resistance in various biological studies. -
COX-2/Carbonic Anhydrase Inhibitor
Polmacoxib is a novel, orally active nonsteroidal anti-inflammatory drug (NSAID) that acts as a dual inhibitor of cyclooxygenase-2 (COX-2) and carbonic anhydrase, with an IC50 value of approximately 0.1 μg/ml for COX-2. It exhibits significant biological activity by inhibiting the growth of colorectal adenomas and tumors in mouse models, making it a promising tool for cancer research. Polmacoxib is valuable for studying the roles of COX-2 and carbonic anhydrase in cancer biology and inflammation. -
COX-2 Inhibitor
COX-2-IN-30 is a benzenesulfonamide derivative that functions as a potent selective inhibitor of cyclooxygenase-2 (COX-2) with an IC50 of 49 nM and also inhibits 5-lipoxygenase (5-LOX) with an IC50 of 2.4 μM. Additionally, it affects human carbonic anhydrase isoforms IX and XII, displaying nanomolar Ki values. This compound demonstrates significant analgesic and anti-inflammatory properties while maintaining a favorable gastrointestinal safety profile, making it useful for research in inflammation, pain relief, and related gastrointestinal studies. -
COX Inhibitor
Aspirin DL-lysine is a lysine-conjugated derivative of aspirin that functions primarily as a cyclooxygenase (COX) inhibitor. This compound effectively inhibits the synthesis of thromboxane A2 (TXA2) in platelets, leading to a reduction in platelet activation and aggregation. Aspirin DL-lysine is valuable for research applications focused on thrombin generation, particularly in clinical studies involving unstable angina pectoris. -
COX-2 Inhibitor
APHS is a selective and covalent inhibitor of cyclooxygenase-2 (COX-2) that exerts neuroprotective effects. By acetylating serine 516 in the active site of COX-2, APHS effectively inhibits prostaglandin production, which is often upregulated in colorectal cancer. In addition to its role as a COX-2 inhibitor, APHS also co-inhibits the WNT signaling pathway, contributing to its anti-tumor mechanisms. This compound is valuable for research into cancer biology and neuroprotection. -
5-LO/COX-2/DPP-4 Inhibitor
Timosaponin A1 is a natural steroidal saponin that acts as an inhibitor of 5-lipoxygenase (5-LO), cyclooxygenase-2 (COX-2), and dipeptidyl peptidase 4 (DPP-4), with IC50 values of 3.29 µM, 36.43 µM, and 33.25 µM, respectively. This compound exhibits anti-inflammatory properties and is relevant for research on conditions such as asthma and diabetes. Its inhibitory effects on key enzymes involved in inflammatory pathways make it a valuable tool for exploring therapeutic strategies in related biological studies. -
COX-2 Inhibitor
Thymohydroquinone is a selective inhibitor of cyclooxygenase-2 (COX-2) with noted anti-SARS-CoV-2 activity. It exhibits cytotoxic properties, antiproliferative effects, and the ability to suppress tumor growth in various cancer models. This compound is applicable in research focused on squamous cell carcinoma, fibrosarcoma, and the pathogenesis and treatment of COVID-19 caused by SARS-CoV-2. -
COX1/2 Inhibitor
Indomethacin sodium is a potent inhibitor of cyclooxygenase enzymes COX-1 and COX-2, exhibiting IC50 values of 18 nM and 26 nM, respectively. This compound demonstrates significant anticancer and anti-infective properties, making it valuable in various biological research applications. Indomethacin sodium is essential for investigating mechanisms related to cancer treatment, inflammation, and viral infections. -
COX-1 Inhibitor
NCX 466 is a selective inhibitor of COX-1 and COX-2, demonstrating notable anti-inflammatory and analgesic properties. It functions as a nitric oxide (NO) donor, enhancing microcirculation while exerting antioxidant effects. NCX 466 effectively reduces levels of transforming growth factor-β (TGF-β) and oxidative stress markers, including thiobarbituric acid reactive substances (TBARS) and 8-hydroxy-2'-deoxyguanosine (8-OHdG). Furthermore, it mitigates leukocyte recruitment during inflammatory responses by decreasing myeloperoxidase (MPO) activity, contributing to the prevention of bleomycin-induced pulmonary fibrosis in murine models. -
COX-2 Inhibitor
Hirsutanonol, a diarylheptanoid derived from the bark of Alnus hirsute var. sibirica, functions primarily as an inhibitor of cyclooxygenase-2 (COX-2). This compound exhibits significant anti-filarial activity, demonstrated by an IC50 value of 44.11 μg/mL against microfilariae. Hirsutanonol is valuable in research focused on inflammation reduction and parasitic disease interventions. -
COX-1 Inhibitor
Dihydroflavokawin B is a selective COX-1 inhibitor, exhibiting an IC50 of 1.22 μM, with moderate effects on COX-2 and 5-LOX. This compound demonstrates significant activity against the promastigote forms of Leishmania panamensis and Leishmania braziliensis, making it a valuable tool for leishmaniasis research. Additionally, Dihydroflavokawin B inhibits rabbit platelet aggregation induced by arachidonic acid, platelet-activating factor, and adenosine diphosphate, highlighting its potential for in vitro anti-inflammatory studies. -
COX Inhibitor
Serratiopeptidase is a zinc-containing metalloprotease that primarily acts as a cyclooxygenase (COX) inhibitor. It effectively reduces the release of inflammatory mediators such as prostaglandins and interleukins, alleviating pain and swelling. In addition to its anti-inflammatory properties, Serratiopeptidase exhibits mucolytic, antibiofilm, and wound-healing activities. Its enzymatic action allows it to dissolve fibrin and blood clots, while also demonstrating potential anti-Alzheimer's effects by degrading amyloid fibrils. Furthermore, Serratiopeptidase shows cytotoxicity against colon cancer cells, making it a versatile reagent for research applications in inflammation and oncology. -
COX-II Inhibitor
Tazofelone is a selective cyclooxygenase-II (COX-II) inhibitor that demonstrates significant anti-inflammatory properties. Its bioactivation to sulfoxide and quinol metabolites is primarily facilitated by the CYP3A enzyme system. This compound is utilized in research related to inflammatory bowel disease, providing valuable insights into potential therapeutic approaches. -
COX Inhibitor
Ibuprofen Impurity F is a specific impurity of Ibuprofen, a well-known anti-inflammatory compound that inhibits cyclooxygenase enzymes COX-1 and COX-2. It exhibits inhibitory activity with IC50 values of 13 μM for COX-1 and 370 μM for COX-2. This reagent is valuable for quality control and analytical characterization in pharmaceutical research and development, particularly in the study of non-steroidal anti-inflammatory drugs (NSAIDs). -
COX Inhibitor
Piroxicam cinnamate is a cyclooxygenase (COX) inhibitor with demonstrated anti-inflammatory properties. It is stable under gastric conditions, making it suitable for research applications focused on inflammatory-degenerative osteoarticular diseases, rheumatic disorders, and varicocele-associated oligoasthenospermia. This compound offers significant potential for investigating therapeutic approaches to various inflammatory conditions. -
COX-1 Inhibitor
Valeryl salicylate is a potent and irreversible inhibitor of cyclooxygenase-1 (COX-1). This compound exhibits significant anti-inflammatory activity, making it a valuable tool for research into inflammatory processes. Its mechanism offers insights into the modulation of COX-1 enzyme activity and potential therapeutic applications in inflammatory conditions. -
COX1/2 Inhibitor
4,4'-Dihydroxy-2,6-dimethoxydihydrochalcone is a selective inhibitor of cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2). This compound demonstrates significant anti-inflammatory properties and is valuable in research aimed at understanding the role of COX enzymes in various disease models. Its application extends to pharmacological studies focused on pain, inflammation, and potential therapeutic interventions. -
COX Inhibitor
Ibuprofen impurity 1 is an impurity of the widely used anti-inflammatory agent ibuprofen, which acts as a dual inhibitor of cyclooxygenase enzymes COX-1 and COX-2, exhibiting IC50 values of 13 μM and 370 μM, respectively. This compound is essential for evaluating the purity and quality of ibuprofen formulations in research. It serves as a valuable tool for studying the pharmacological effects and potential side effects of ibuprofen in various biological assays. -
COX-2 Inhibitor
Robenacoxib is a selective cyclooxygenase-2 (COX-2) inhibitor with potent anti-inflammatory and analgesic properties. It primarily reduces the production of prostaglandins associated with inflammation and pain, making it valuable for research related to inflammatory diseases and pain management. This compound is utilized in studies aiming to elucidate the role of COX-2 in various biological processes and to develop therapeutic strategies targeting inflammation. -
COX-2 Inhibitor
3-Carene is a bicyclic monoterpene that functions as a cyclooxygenase-2 (COX-2) inhibitor. It demonstrates significant anti-inflammatory properties by reducing nociceptive stimulus-induced inflammatory infiltrates and decreasing COX-2 overexpression. Additionally, 3-Carene enhances both the activity and expression of alkaline phosphatase, a crucial early marker of osteoblastic differentiation, making it a valuable compound for research in pain management and bone health. -
COX-2 Inhibitor
Mavacoxib is a selective, oral cyclooxygenase-2 (COX-2) inhibitor, functioning as a long-acting non-steroidal anti-inflammatory drug (NSAID). This compound effectively alleviates pain and inflammation related to degenerative joint disease, particularly in canine subjects. Research applications include studies on inflammation and pain management in veterinary medicine. -
COX-2 Inhibitor
Desmethyl Celecoxib is a selective inhibitor of cyclooxygenase-2 (COX-2) with an IC50 value of 32 nM, demonstrating significant anti-inflammatory activity. As an analog of Celecoxib, this compound serves as a valuable tool in research applications focusing on inflammation and pain pathways. Its potency and specificity make it suitable for studies related to COX-2 mediated processes. -
5-LO/COX Inhibitor
BW 755C is a dual inhibitor of 5-lipoxygenase (5-LO) and cyclooxygenase (COX) enzymes, exhibiting an IC50 of 5 μM for 5-LO. It also demonstrates inhibitory activity against COX-1 and COX-2, with IC50 values of 0.65 and 1.2 μg/mL, respectively. This compound is valuable for research applications involving inflammation and other related pathways. Its ability to concurrently inhibit key lipid mediators makes BW 755C a useful tool in studies focused on arachidonic acid metabolism and signaling pathways. -
COX-2 Inhibitor
Enflicoxib is a selective inhibitor of cyclooxygenase-2 (COX-2), a key enzyme in the inflammatory pathway. This nonsteroidal anti-inflammatory compound exhibits notable anti-inflammatory, analgesic, and antipyretic effects in various animal models. Enflicoxib is valuable for research investigating COX-2-mediated processes and potential therapeutic applications in pain management and inflammation. -
COX-1 Inhibitor
CP-74006 is a selective inhibitor of Cyclooxygenase-1 (COX-1). This compound demonstrates significant anti-inflammatory activity by blocking the conversion of arachidonic acid to prostaglandins, key mediators in the inflammatory response. CP-74006 is utilized in research focusing on inflammation, pain management, and cardiovascular disease, providing valuable insights into COX-1 related biological processes. -
COX inhibitor
2-Chloro-N-(2,6-dimethylphenyl)acetamide is a cyclooxygenase (COX) inhibitor that modulates inflammatory responses by inhibiting the conversion of arachidonic acid to prostaglandins. Its biological activity makes it a valuable tool in research focused on inflammation and pain pathways. This compound is utilized for studying COX-related mechanisms in various biological contexts, potentially aiding in the development of anti-inflammatory therapies. -
COX- 2 Inhibitor
Ocarocoxib is a selective cyclooxygenase-2 (COX-2) inhibitor with an IC50 value of 1.4 μM. By inhibiting COX-2, Ocarocoxib effectively reduces the synthesis of prostaglandins, thereby imparting significant anti-inflammatory effects. This compound is useful for research on inflammation and associated pathological conditions. -
COX-2/5-LOX Inhibitor
Tebufelone is a selective dual inhibitor of cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LO). It exhibits significant anti-inflammatory, analgesic, and antipyretic properties, making it useful for research into inflammatory pathways. This compound is valuable for studying the roles of COX-2 and 5-LO in various biological processes and assessing novel therapeutic strategies for inflammatory diseases. -
COX-1 Inhibitor
Teriflunomide impurity 3, also known as 4-Amino-N-(4-trifluoromethylphenyl)benzamide, acts as a selective inhibitor of cyclooxygenase-1 (COX-1) with an IC50 of 30 µM. This compound exhibits significantly lower activity against COX-2, with an IC50 greater than 100 µM. Teriflunomide impurity 3 is valuable for research applications exploring inflammatory pathways and the role of COX-1 in various biological processes. -
COX
ASP6537 is a selective inhibitor of recombinant human cyclooxygenase-1 (rhCOX-1), exhibiting an IC50 value of 0.703 nM. Its potent inhibition of COX-1 makes it a valuable tool for studying the role of prostaglandins in cardiovascular disease research. Researchers can utilize ASP6537 to investigate the effects of COX-1 modulation on cardiovascular pathophysiology. -
iNOS/COX-2 Inhibitor
Rehmapicrogenin is a selective inhibitor of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2). This compound, derived from the root of Rehmannia glutinosa, demonstrates significant anti-inflammatory properties, making it a valuable tool for research focused on inflammation pathways. Its ability to inhibit pro-inflammatory mediators such as IL-6 further underscores its relevance in studies aimed at understanding and treating inflammatory diseases. -
COX-1/COX-2 Inhibitor
(S)-(+)-Ibuprofen-d3 is a deuterated analog of (S)-(+)-Ibuprofen, targeting the COX-1 and COX-2 enzymes. With IC50 values of 2.1 μM and 1.6 μM, respectively, this compound exhibits significant analgesic, anti-inflammatory, and antipyretic properties. It serves as a valuable tool for studying the pharmacodynamics and mechanisms of nonsteroidal anti-inflammatory drugs (NSAIDs) in various biological research applications. -
COX Inhibitor
Isoxicam is a non-steroidal anti-inflammatory drug (NSAID) that functions as a nonselective inhibitor of cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2). Its primary mechanism involves the inhibition of prostaglandin synthesis, making it effective in reducing inflammation and pain. Isoxicam is commonly utilized in research related to arthritis and other inflammatory conditions, providing valuable insights into the role of COX enzymes in various biological processes. -
COX-2 Inhibitor
Cimicoxib is a selective COX-2 inhibitor that effectively penetrates the blood-brain barrier. It displays significant anti-inflammatory, analgesic, and antipyretic properties by inhibiting the production of thromboxane B2 and prostaglandin E2, with an IC50 of 66 nM against human COX-2. Additionally, Cimicoxib targets CYP2D15, exhibiting an IC50 of 1.6 μM in canines and 0.056 μM in felines. This compound is utilized in research involving inflammatory diseases, osteoarthritis, and perioperative pain management in orthopedic and soft tissue surgeries. -
COX Inhibitor
Naproxen glucuronide, a metabolite of naproxen, functions as a non-selective cyclooxygenase (COX) inhibitor. This compound exhibits significant anti-inflammatory, analgesic, and antipyretic activity, making it useful in the study of pain relief and inflammation pathways. Research applications include examining its metabolic pathways, assessing its efficacy in various inflammatory conditions, and exploring its pharmacokinetic properties in biological systems. -
Dual COX/5-LOX Inhibitor
ER-34122 is a dual inhibitor of cyclooxygenase (COX) and 5-lipoxygenase (5-LO). This compound exhibits significant anti-inflammatory activity, making it valuable for research into inflammation-related pathways. ER-34122 is particularly relevant for studies investigating the interplay between COX and 5-LO pathways in various disease models and therapeutic contexts. -
COX-2 Inhibitor
Apricoxib is a selective inhibitor of cyclooxygenase-2 (COX-2), demonstrating a potent inhibitory effect on PGE2 production with an IC50 of 1.5 nM. This compound exhibits notable biological activities, including anticancer, analgesic, and anti-inflammatory properties. Apricoxib is a valuable tool for research applications focused on inflammation, pain management, and cancer therapeutics. -
COX-2/PGE2 Inducer
Rebamipide-d4 is a deuterium-labeled derivative of Rebamipide, primarily targeting cyclooxygenase-2 (COX-2). This compound induces COX-2 expression and elevates prostaglandin E2 (PGE2) levels, thereby enhancing gastric mucosal defense mechanisms in a COX-2-dependent manner. Rebamipide-d4 is utilized in various research applications focused on gastric protection and the modulation of inflammatory responses. -
Etoricoxib Metabolite
Etoricoxib N1'-oxide is a metabolite of Etoricoxib that serves as an important biochemical marker in pharmacological studies. This compound is notable for its lack of inhibition on both COX-1 and COX-2 enzymes, making it a valuable tool for researchers investigating the metabolic pathways and safety profiles of COX inhibitors. Its characterization can aid in understanding the pharmacodynamics and pharmacokinetics of Etoricoxib in clinical settings. -
COX Inhibitor
SC57666 is a selective inhibitor of cyclooxygenase-2 (COX-2) with an IC50 value of 26 nM. This compound exhibits anti-inflammatory activity by specifically blocking COX-2, thereby reducing prostaglandin synthesis. SC57666 is valuable for research applications focused on understanding inflammation and pain mechanisms, as well as for screening in drug discovery efforts targeting COX-2 related conditions.
